领航医药生物科技拟折让约17.84%配售最多2.06亿股净筹3552万港元

格隆汇2025-05-29

格隆汇5月29日丨领航医药生物科技(00399.HK)公告，于2025年5月29日，公司与配售代理订立配售协议，据此，配售代理已有条件同意担任公司代理，以竭诚促使目前预期不少于六名承配人(彼等及其最终实益拥有人应为独立第三方)按每股配售股份0.175港元的配售价认购最多206,400,000股配售股份。假设公司已发行股本于本公告日期至完成配售事项日期期间不会有变，最多206,400,000股配售...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2539269911?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-29 22:21","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2539269911","market":"hk","top_or_hot":-1,"title":"领航医药生物科技拟折让约17.84%配售最多2.06亿股 净筹3552万港元","media":"格隆汇","content":"<div>\n<p>格隆汇5月29日丨领航医药生物科技(00399.HK)公告，于2025年5月29日，公司与配售代理订立配售协议，据此，配售代理已有条件同意担任公司代理，以竭诚促使目前预期不少于六名承配人(彼等及其最终实益拥有人应为独立第三方)按每股配售股份0.175港元的配售价认购最多206,400,000股配售股份。假设公司已发行股本于本公告日期至完成配售事项日期期间不会有变，最多206,400,000股配售...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250529222421a4917a49&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>领航医药生物科技拟折让约17.84%配售最多2.06亿股 净筹3552万港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n领航医药生物科技拟折让约17.84%配售最多2.06亿股 净筹3552万港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-29 22:21 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250529222421a4917a49&s=b><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>格隆汇5月29日丨领航医药生物科技(00399.HK)公告，于2025年5月29日，公司与配售代理订立配售协议，据此，配售代理已有条件同意担任公司代理，以竭诚促使目前预期不少于六名承配人(彼等及其最终实益拥有人应为独立第三方)按每股配售股份0.175港元的配售价认购最多206,400,000股配售股份。假设公司已发行股本于本公告日期至完成配售事项日期期间不会有变，最多206,400,000股配售...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250529222421a4917a49&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00399","symbol_name":"星太链集团","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250529222421a4917a49&s=b","article_id":"2539269911","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250529222421a4917a49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2539269911","pubTimestamp":1748528460,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"格隆汇5月29日丨领航医药生物科技公告，于2025年5月29日，公司与配售代理订立配售协议，据此，配售代理已有条件同意担任公司代理，以竭诚促使目前预期不少于六名承配人按每股配售股份0.175港元的配售价认购最多206,400,000股配售股份。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"00399":"星太链集团","BK1124":"贸易公司与经销商"},"translate_title":"Linghang Pharmaceutical Biotechnology plans to place up to 206 million shares at a discount of approximately 17.84%, raising a net of HK $35.52 million","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00399":1},"content_text":"格隆汇5月29日丨领航医药生物科技(00399.HK)公告，于2025年5月29日，公司与配售代理订立配售协议，据此，配售代理已有条件同意担任公司代理，以竭诚促使目前预期不少于六名承配人(彼等及其最终实益拥有人应为独立第三方)按每股配售股份0.175港元的配售价认购最多206,400,000股配售股份。假设公司已发行股本于本公告日期至完成配售事项日期期间不会有变，最多206,400,000股配售股份占于本公告日期公司现有已发行股本约11.32%；每股配售股份0.175港元的配售价较股份于2025年5月29日(即配售协议日期)在联交所所报收市价每股0.213港元折让约17.84%；所得款项净额估计约为3552万港元。公司拟将配售事项所得款项净额全数用作集团的一般营运资金。追加内容本文作者可以追加内容哦 !","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2539269911","isCrawlerRequest":true}

领航医药生物科技拟折让约17.84%配售最多2.06亿股 净筹3552万港元

精彩评论

领航医药生物科技拟折让约17.84%配售最多2.06亿股净筹3552万港元